• Consensus Rating: Hold
  • Consensus Price Target: $32.00
  • Forecasted Upside: 184.77 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$11.24
▲ +0.64 (6.04%)

This chart shows the closing price for VALN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Valneva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VALN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VALN

Analyst Price Target is $32.00
▲ +184.77% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Valneva in the last 3 months. The average price target is $32.00, with a high forecast of $32.00 and a low forecast of $32.00. The average price target represents a 184.77% upside from the last price of $11.24.

This chart shows the closing price for VALN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Valneva. This rating has held steady since September 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/23/2022The Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
8/19/2022HC WainwrightLower TargetBuy$34.00 ➝ $32.00Low
8/3/2022HC WainwrightInitiated CoverageBuy$34.00Low
7/28/2022Kepler Capital MarketsDowngradeBuy ➝ HoldLow
12/22/2021UBS GroupDowngradeNeutral ➝ SellLow
9/24/2021Jefferies Financial GroupInitiated CoverageBuy$39.00Low
9/13/2021Bryan, Garnier & CoDowngradeBuy ➝ NeutralHigh
6/30/2021Kepler Capital MarketsReiterated RatingBuyLow
6/1/2021Jefferies Financial GroupInitiated CoverageBuy$36.00High
6/1/2021The Goldman Sachs GroupInitiated CoverageBuy$34.00High
5/31/2021GuggenheimInitiated CoverageBuy$35.00High
(Data available from 9/28/2017 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/2/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 10 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2022
  • 11 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/31/2022
  • 21 very positive mentions
  • 32 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/30/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/30/2022
  • 4 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/29/2022
  • 9 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/28/2022

Current Sentiment

  • 9 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Valneva logo
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Read More

Today's Range

Now: $11.24
Low: $10.86
High: $11.61

50 Day Range

MA: $17.87
Low: $10.59
High: $21.42

52 Week Range

Now: $11.24
Low: $10.59
High: $67.84

Volume

4,168 shs

Average Volume

30,596 shs

Market Capitalization

$659.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Valneva?

The following Wall Street research analysts have issued research reports on Valneva in the last twelve months: HC Wainwright, Kepler Capital Markets, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for VALN.

What is the current price target for Valneva?

1 Wall Street analysts have set twelve-month price targets for Valneva in the last year. Their average twelve-month price target is $32.00, suggesting a possible upside of 184.8%. HC Wainwright has the highest price target set, predicting VALN will reach $32.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $32.00 for Valneva in the next year.
View the latest price targets for VALN.

What is the current consensus analyst rating for Valneva?

Valneva currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VALN, but not buy more shares or sell existing shares.
View the latest ratings for VALN.

What other companies compete with Valneva?

How do I contact Valneva's investor relations team?

The company's listed phone number is 33-2-28-07-37-10 and its investor relations email address is [email protected] The official website for Valneva is valneva.com. Learn More about contacing Valneva investor relations.